The risk of developing blood clots after a J&J shot is extremely rare, and the benefits of the shot outweigh any potential risks, officials say
A Washington woman has succumbed to a rare clotting syndrome after receiving J&J COVID-19 Vaccine, confirming the first such death in the state, health officials announced.
The woman, whose name was not disclosed by county or state health officials, was in her late 30s and a resident of King County. She received the vaccine on August 26, 2021 and died a week later on September 7. Statement.
Rare clot risk associated with Johnson & Johnson COVID-19 vaccine needs to be explained to younger women, CDC says
The cause of death was thrombocytopenia syndrome (TTS), which described TTS as a rare but serious condition among those receiving the J&J vaccine, according to Seattle and King County Public Health. While the CDC’s Clinical Immunization Safety Assessment Project confirmed the diagnosis, officials noted, the CDC has reported three other confirmed deaths nationwide from the complication.
“Sadly, this is the first such death in Washington state,” said the state’s health secretary, Dr. Umair A. Shah said in one Statement Posted Tuesday. “We send our deepest condolences to his family and loved ones. Losing a loved one at any time is a sad and difficult … pain that has become all too familiar in the past year and a half of this pandemic.”
The state health department said it would work closely with county and federal health officials when more details become available.
In late April, federal health officials called J&J . Removed the 11-day break on the use of COVID-19 Vaccination After the review and recommendation of a panel of experts to determine the safety standards met Despite rare instances of severe blood clots.
“We have concluded that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older,” FDA Commissioner Janet Woodcock said in a previous statement. “We are confident that this vaccine will continue to meet our standards for safety, effectiveness and quality.”
Fact sheets with the J&J COVID-19 Vaccine Alert remote exposure to blood clots and low levels of platelets, with symptoms usually appearing within two weeks after vaccination. Women ages 18-49 are associated with the highest reporting rates. Despite the rare risk, health officials recommend seeking immediate medical attention for the following symptoms after receiving the J&J shot, such as shortness of breath, chest pain, swelling of the legs, persistent abdominal pain, severe or persistent headache or Blurred vision and easy bruising or small spots of blood under the skin beyond the injection site.